Regensburg (Germany), September 20th 2021 — lifespin, a deep data company created to map human health based on digitized metabolomic profiles, is an inaugural member of the Wyss DxA IPP at Harvard’s Wyss Institute. The mission of Wyss DxA to create and deliver disruptive diagnostic technologies to address unmet clinical needs in the screening, diagnosis, prognosis, and management of diseases is in full alignment with lifespin’s mission to revolutionize healthcare by creating a digital atlas of human health to provide deeper clinical insight based on metabolomic information.
“lifespin’s propriety platform for the analysis of metabolites will disrupt how clinical chemistry is done and drive individualized medicine,” states Dr. Felix Wieland, elected Member of the National Academy of Sciences Leopoldina, Senior Professor for Biochemistry at Heidelberg University, lifespin Board Member, and Honorary Member of the Charité.
Being the first program of its kind within the Harvard biomedical system, the IPP creates the foundation for the partners to build a mutually beneficial framework for tackling hard-to-solve problems in the discovery, development, and delivery of diagnostic solutions in areas of unmet needs.
The Wyss DxA IPP was created with the understanding that the involvement of the private sector is an essential component of the new Wyss DxA model aiming to disrupt today’s diagnostics. “It is a win-win situation for all groups involved, but most of all for patients with disease risks that simply cannot be assessed yet in a timely and accurate manner, and for monitoring the effectiveness of new therapies with the necessary precision in clinical trials,” said the Head of the Wyss DxA, Rushdy Ahmad, Ph.D.
“We are very honored to be selected and invited as one of the first members of the IPP,” states lifespin’s CEO, Dr. Ali Tinazli. “Collaborating with world-class talent at the Wyss Institute and other IPP member will help support our objective to use digital metabolic profiles for early detection of health conditions, staging of diseases, and monitoring treatment success” Tinazli said.
Dr. Ali Tinazli, CEO, email@example.com, +49 941-942-898-12